Skip to main content
. 2021 May;74(5):1064–1074. doi: 10.1016/j.jhep.2020.11.043

Fig. 1.

Fig. 1

Patient outcome and viral kinetics after NA discontinuation. (A) Patient outcome after NA discontinuation. Bars represent the percentage of patients with HBsAg loss, virological control, or re-treatment. The number of patients is shown within the bars. (B) HBV-DNA, HBsAg, and ALT kinetics. For re-treated patients, the dotted line represents the evolution after treatment re-introduction. ALT, alanine aminotransferase; NA, nucleos(t)ide analogue.